AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7864430 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative enalaprilat (1.25 mg intravenously [i.v.] 20 min prior to induction)
Number of subjects: 30
Study 7864430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative enalaprilat (0.625 mg i.v. at the onset of tourniquet‐associated hypertension)
Number of subjects: 30
Study 7864430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1685993 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0
Study 1685993 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 1685993 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 1685993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7021140 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (Rivotril)
Number of subjects: 36
Study 7021140 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (Tegretol)
Number of subjects: 36
Study 31974142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 3065
Study 31974142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3065
Study 31427326 — intervention group
Group type: EXPERIMENTAL
Intervention: Genie intervention
Number of subjects: 0
Study 31427326 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 28959492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 3310
Study 28959492 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 3310
Study 27002298 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabodenoson 500 mcg
Number of subjects: 0
Study 27002298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24647384 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention providing personalized CVD risk information and behavioral/lifestyle modules (3-month duration).
Number of subjects: 96
Study 24647384 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 96
Study 21799028 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS + LABA + Tio
Number of subjects: 2853
Study 21799028 — intervention group
Group type: COMPARATOR
Intervention: ICS + LABA
Number of subjects: 2853
Study 19490181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (DF), n=23
Number of subjects: 47
Study 19490181 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC), n=24
Number of subjects: 47
Study 19490181 — intervention group
Group type: COMPARATOR
Intervention: Thymidine NRTIs (zidovudine and stavudine), n=11 and n=36 respectively
Number of subjects: 47
Study 17241298 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC7 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 598
Study 17241298 — intervention group
Group type: COMPARATOR
Intervention: PAC14 group (same regimen for 14 days)
Number of subjects: 598
Study 16079650 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of aerobic training
Number of subjects: 18
Study 16079650 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary lifestyle)
Number of subjects: 18
Study 11986086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir 1% four times daily
Number of subjects: 34
Study 11986086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir 1% ten times daily
Number of subjects: 34
Study 11986086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir 1% four times daily and Cyclosporin A 1% four times daily
Number of subjects: 34
Study 11986086 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride four times daily
Number of subjects: 34
Study 9704869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (1200 mg)
Number of subjects: 16
Study 9704869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7625773 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol administration (20 g) alone
Number of subjects: 13
Study 7625773 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol administration (20 g) with a mixed meal
Number of subjects: 13
Study 7625773 — intervention group
Group type: COMPARATOR
Intervention: Mixed meal alone
Number of subjects: 13
Study 7625773 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol administration (20 g)
Number of subjects: 13
Study 30947531 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release bupropion (switch)
Number of subjects: 1522
Study 30947531 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release bupropion (combination)
Number of subjects: 1522
Study 30947531 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole (augmentation)
Number of subjects: 1522
Study 28114909 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity treatment (HIT) composed of low glycemic index diet + exercise + vitamin D (60ng/mL serum concentration)
Number of subjects: 506
Study 28114909 — intervention group
Group type: COMPARATOR
Intervention: Lower intensity treatment (LITE) with general advice to follow a healthy diet and exercise pattern + vitamin D to avoid insufficiency
Number of subjects: 506
Study 25451240 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA-ergic neurotransmission via alprazolam (GABAA receptor agonist)
Number of subjects: 0
Study 25451240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23660044 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (not specified in detail)
Number of subjects: 0
Study 23660044 — intervention group
Group type: COMPARATOR
Intervention: Baseline self-confidence scores
Number of subjects: 0
Study 23660044 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of vaginal hysterectomies performed before the educational intervention
Number of subjects: 0
Study 23660044 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-confidence scale
Number of subjects: 0
Study 20413036 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP infusion (0.02 microg/kg/min)
Number of subjects: 133
Study 20413036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 133
Study 17953462 — intervention group
Group type: EXPERIMENTAL
Intervention: OGT oral spray taken five times daily
Number of subjects: 41
Study 17953462 — intervention group
Group type: COMPARATOR
Intervention: Saliveze
Number of subjects: 41
Study 15590244 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory therapy (n = 36 sessions for 12 weeks)
Number of subjects: 89
Study 15590244 — intervention group
Group type: COMPARATOR
Intervention: Activity therapy (n = 36 sessions for 12 weeks)
Number of subjects: 89
Study 12395981 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet containing rifampicin, isoniazid, pyrazinamide, and ethambutol
Number of subjects: 14
Study 12395981 — intervention group
Group type: COMPARATOR
Intervention: Separate formulations of rifampicin, isoniazid, and pyrazinamide
Number of subjects: 14
Study 10395837 — intervention group
Group type: COMPARATOR
Intervention: Zanamivir 2x daily for 5 days
Number of subjects: 1256
Study 10395837 — intervention group
Group type: COMPARATOR
Intervention: Zanamivir 4x daily for 5 days
Number of subjects: 1256
Study 10395837 — intervention group
Group type: COMPARATOR
Intervention: Zanamivir
Number of subjects: 1256
Study 7675961 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 91
Study 7675961 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 91
Study 2115407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous recombinant tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 1 hour)
Number of subjects: 67
Study 2115407 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous rt-PA (0.75 mg/kg over 1 hour; total dose, 100 mg over 6 hours)
Number of subjects: 67
Study 2115407 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 67
Study 2115407 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (low-dose rt-PA, high-dose rt-PA, placebo)
Number of subjects: 67
Study 6111212 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 9
Study 6111212 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg daily
Number of subjects: 9
Study 6111212 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 or 200 mg)
Number of subjects: 9
Study 31488064 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus HCV/HIV-Reduction Education Program (HCV/HIV-REP) for 24 weeks
Number of subjects: 240
Study 31488064 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 12 weeks
Number of subjects: 240
Study 29273083 — intervention group
Group type: COMPARATOR
Intervention: Information and advice
Number of subjects: 600
Study 29273083 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and information and advice
Number of subjects: 600
Study 29273083 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care and information and advice
Number of subjects: 600
Study 29273083 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care, physiotherapy, and information and advice
Number of subjects: 600
Study 26525962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco-heating cigarettes
Number of subjects: 150
Study 26525962 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 150
Study 26525962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low machine yield tobacco-burning cigarettes
Number of subjects: 150
Study 26525962 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual brand cigarettes)
Number of subjects: 150
Study 25146062 — intervention group
Group type: EXPERIMENTAL
Intervention: Seidlitzia rosmarinus plus prazosin 1mg/day
Number of subjects: 98
Study 25146062 — intervention group
Group type: COMPARATOR
Intervention: Prazosin 1mg/day
Number of subjects: 98
Study 20852079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary florfenicol (0.02 g/kg; 16 wk)
Number of subjects: 48
Study 20852079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of florfenicol (0.02 g/kg; 8 wk) and DVAQUA (0.5 g/kg; 8 wk)
Number of subjects: 48
Study 20852079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary DVAQUA (0.5 g/kg; 16 wk)
Number of subjects: 48
Study 20852079 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 19552597 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 21
Study 17633908 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized telephone intervention program delivering continuity of care by a multidisciplinary team
Number of subjects: 9000
Study 17633908 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9000
Study 17633908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in advanced functional class
Number of subjects: 9000
Study 17633908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischemic etiology
Number of subjects: 9000
Study 17633908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in NYHA class I-II and without ischemic etiology
Number of subjects: 9000
Study 17633908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients admitted for decompensated heart failure
Number of subjects: 9000
Study 16381264 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.04 microg/kg/min
Number of subjects: 50
Study 16381264 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion starting at 2 mg/kg/h reduced to 1 mg/kg/h
Number of subjects: 50
Study 16381264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Remifentanil and Propofol)
Number of subjects: 50
Study 12215235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release (SR) for 12 weeks
Number of subjects: 68
Study 12215235 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 68
Study 12215235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release (SR)
Number of subjects: 68
Study 12215235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9468749 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint Scale (RS)
Number of subjects: 104
Study 9468749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restraint Scale of the Three Factor Eating Questionnaire (TFEQ‐CR)
Number of subjects: 104
Study 9468749 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood manipulation
Number of subjects: 104
Study 9468749 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood manipulation
Number of subjects: 104
Study 8904056 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (80 mg daily)
Number of subjects: 126
Study 8904056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 1974142 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 20 micrograms kg‐1 + somatostatin + trimetaphan
Number of subjects: 18
Study 1974142 — intervention group
Group type: COMPARATOR
Intervention: sufentanil + sodium nitroprusside
Number of subjects: 18
Study 1974142 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil + somatostatin + trimetaphan
Number of subjects: 18
Study 64972 — intervention group
Group type: EXPERIMENTAL
Intervention: programmed instruction (PI)
Number of subjects: 137
Study 64972 — intervention group
Group type: EXPERIMENTAL
Intervention: audiovisual (AV)
Number of subjects: 137
Study 64972 — intervention group
Group type: EXPERIMENTAL
Intervention: AV-PI combined
Number of subjects: 137
Study 64972 — intervention group
Group type: COMPARATOR
Intervention: no exposure to the mini-course (control group)
Number of subjects: 137
Study 30920097 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Gold Label 1 Luting & Lining (GIC)
Number of subjects: 30
Study 30920097 — intervention group
Group type: EXPERIMENTAL
Intervention: Relyx U200 (RUC)
Number of subjects: 30
Study 30920097 — intervention group
Group type: COMPARATOR
Intervention: Relyx ARC (RAC)
Number of subjects: 30
Study 29800096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie (n=381)
Number of subjects: 757
Study 29800096 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube + stylet (n=376)
Number of subjects: 757
Study 26655421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg daily orally) with bendamustine plus rituximab
Number of subjects: 578
Study 26655421 — intervention group
Group type: COMPARATOR
Intervention: Placebo with bendamustine plus rituximab
Number of subjects: 578
Study 24576466 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed egoistic action
Number of subjects: 0
Study 24576466 — intervention group
Group type: COMPARATOR
Intervention: Completed altruistic action
Number of subjects: 0
Study 24576466 — intervention group
Group type: COMPARATOR
Intervention: Intended (im)moral actions
Number of subjects: 0
Study 22992073 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 (dimethyl fumarate) 240 mg twice daily
Number of subjects: 0
Study 22992073 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 (dimethyl fumarate) 240 mg three times daily
Number of subjects: 0
Study 22992073 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 (dimethyl fumarate)
Number of subjects: 0
Study 22992073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19240689 — intervention group
Group type: EXPERIMENTAL
Intervention: NV1FGF plasmid DNA (0.5, 2, or 4 mg administered as eight IM injections)
Number of subjects: 6
Study 17030096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 50
Study 17030096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15699265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 10
Study 15699265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15699265 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg)
Number of subjects: 10
Study 11874743 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 2819
Study 11874743 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility visual field tests
Number of subjects: 2819
Study 11874743 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat test after abnormal or unreliable test
Number of subjects: 2819
Study 11874743 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% fixation loss cutoff
Number of subjects: 2819
Study 10022444 — intervention group
Group type: EXPERIMENTAL
Intervention: Human BNP infusion (3.0 pmol/kg min)
Number of subjects: 8
Study 10022444 — intervention group
Group type: EXPERIMENTAL
Intervention: NEP inhibitor (SCH 42495, 300 mg)
Number of subjects: 8
Study 10022444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BNP and NEP inhibitor
Number of subjects: 8
Study 10022444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7778470 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure greater than 85 mmHg
Number of subjects: 1070
Study 7778470 — intervention group
Group type: COMPARATOR
Intervention: Low or normal diastolic blood pressure
Number of subjects: 1070
Study 7778470 — intervention group
Group type: COMPARATOR
Intervention: Low blood pressure
Number of subjects: 1070
Study 2081639 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated lyophilized Schwartz strain of measles vaccine
Number of subjects: 132
Study 2081639 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated group
Number of subjects: 132
Study 7002178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofizopam 100 mg
Number of subjects: 146
Study 7002178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 146
Study 7002178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on 9 preoperative risk factors
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative delirium
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dementia
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 70-79
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 80-89
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥90
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical comanagement
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA physical status III-V
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dependence
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response syndrome/sepsis/septic shock
Number of subjects: 8871
Study 31478933 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative use of mobility aid
Number of subjects: 8871
Study 31657508 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism-Focused Public Speech Training using Simple Virtual Audiences (APSV)
Number of subjects: 15
Study 31657508 — intervention group
Group type: COMPARATOR
Intervention: Independent Study (IS)
Number of subjects: 15
Study 29970053 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplements provided by trained BRAC village volunteers during early pregnancy
Number of subjects: 30000
Study 29970053 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 30000
Study 27378790 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 μg/kg/min for 24 h without a loading dose)
Number of subjects: 32
Study 27378790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23937690 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation (1 Hz for 1 min) over both left and right angular gyrus (AG)
Number of subjects: 15
Study 23937690 — intervention group
Group type: EXPERIMENTAL
Intervention: Right AG-rTMS
Number of subjects: 15
Study 23937690 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 22781640 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 172
Study 22781640 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine therapy only)
Number of subjects: 172
Study 20429955 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 24
Study 20429955 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 24
Study 20429955 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-ATM
Number of subjects: 24
Study 18729579 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair writing task
Number of subjects: 305
Study 18729579 — intervention group
Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 305
Study 15906078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise (90% of the individual anaerobic threshold for 60-90 min)
Number of subjects: 17
Study 15906078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure eccentric down jumps (9 x 28 isolated down jumps in 90 min, drop from a height of 55 cm)
Number of subjects: 17
Study 15906078 — intervention group
Group type: COMPARATOR
Intervention: Control experiment
Number of subjects: 17
Study 12728461 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ppm NO via inhalation followed by a recruitment maneuver (RM) with sustained inflation pressure of 30‐35 cmH2O for 30 seconds (Group 1)
Number of subjects: 23
Study 12728461 — intervention group
Group type: COMPARATOR
Intervention: Recruitment maneuver (RM) alone (Group 2)
Number of subjects: 23
Study 12728461 — intervention group
Group type: COMPARATOR
Intervention: NO inhalation alone (Group 3)
Number of subjects: 23